Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T‐cell leukemia virus type I‐associated myelopathy/tropical spastic paraparesis
Open Access
- 29 August 2024
- journal article
- research article
- Published by Wiley in IJU Case Reports
- Vol. 7 (6) , 438-441
Abstract
Introduction: Human T‐cell lymphotropic virus type 1 infection can cause HTLV‐1‐associated myelopathy/tropical spastic paraparesis, characterized by spastic paralysis of both lower limbs. More than 90% of HAM/TSP patients show lower urinary tract symptoms and dysfunction.Case presentation: A 27‐year‐old woman diagnosed with HAM/TSP presented with overactive bladder. A urodynamic study revealed detrusor overactivity. OAB remained despite improvements in spastic paralysis of the lower limbs after starting prednisolone. The addition of solifenacin likewise failed to improve OAB or DO in this patient. Switching from solifenacin to vibegron improved OAB symptoms.Conclusion: In patients for whom OAB and DO do not improve with steroid treatment and solifenacin, treatment with vibegron may improve OAB symptoms.Keywords
This publication has 15 references indexed in Scilit:
- Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in JapanOrphanet Journal of Rare Diseases, 2021
- Prevalence of Sjögren's syndrome in Brazilian patients infected with human T‐cell lymphotropic virusJournal of Oral Pathology & Medicine, 2016
- The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly menBMC Urology, 2016
- Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?Case Reports in Medicine, 2011
- Impact of HTLV-I in quality of life and urogynecologic parameters of women with urinary incontinenceEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- Afferent Nerve Regulation of Bladder Function in Health and Disease2009
- M 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary glandNaunyn-Schmiedeberg's Archives of Pharmacology, 2002
- M2 receptors in genito-urinary smooth muscle pathologyLife Sciences, 1999
- HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITYThe Lancet, 1986
- ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESISThe Lancet, 1985